Timothy Robert Sampson

This study shows antipsychotics alter gut microbiota and metabolome, increasing susceptibility to infection in mice.

This study identifies dysbiotic gut microbiome features in Parkinson's disease, links them to genetic variants, and proposes microbiome-based biomarkers for targeted treatment.

This study shows that gut microbes influence the transcriptional states of brain cell types and affect neurodegenerative disease susceptibility, with E. coli specifically worsening Alzheimer's disease outcomes in mice.

This study shows the gut microbiome is necessary for host detoxification responses to deltamethrin, with both developmental and active microbial signaling contributing to hepatic and colonic detoxification.

This study shows deltamethrin disrupts monoamine and neuropeptide signaling in EECs, leading to reduced intestinal motility and hormone release.

This study shows that alpha-synuclein overexpression in mice alters gut microbiome composition with age, suggesting a potential link between PD pathology and microbiome dysbiosis.

This study shows that dietary fiber and microbiome-derived metabolites protect the enteric nervous system after spinal cord injury by modulating immune signaling.

The paper assesses cognitive and motor function in APPSAA and APPWT mice over 12 months, finding no age-related cognitive decline but increased fecal output in APPSAA mice.

The paper shows that a high-fat, high-carbohydrate diet causes sex-specific metabolic and inflammatory issues in 5xFAD mice, which are partially reversed by inhibiting soluble TNF in males.

The paper develops microbiome-based biomarkers to identify suitable patients for microbiome-based therapies in Parkinson's disease, showing that not all patients have dysbiotic microbiomes and that dysbiotic microbiomes vary in features.

This study investigates the gut microbiome's role in Parkinson's disease using metagenomics, finding widespread dysbiosis and associations with disease mechanisms.